Cat. No. 5955
Chemical Name: 3-(2-Amino-5-benzoxazolyl)-1-(2,2-d
Biological ActivityPotent mTOR inhibitor (IC50 = 15 nM). Exhibits >60-fold selectivity for mTOR over PI 3-kinases and is inactive against a panel of other kinases. Inhibits growth of ER-positive MCF7 breast cancer cells in vitro (EC50 = 8.5 nM). Cell permeable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Fraser et al (2016) eCF309: a potent, selective and cell-permeable mTOR inhibitor Med.Chem.Commun. 4 471.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses eCF 309 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: eCF 309, supplier, eCF309, mTOR, inhibitors, inhibits, potent, anticancer, Tocris Bioscience, mTOR Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailablePF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitorAZ PFKFB3 67
Potent and selective PFKFB3 inhibitorSTOCK2S 26016
Lysine deficient protein kinase (WNK) signaling inhibitorrac-CCT 250863
Potent Nek2 inhibitorRoscovitine
Potent, selective cyclin-dependent kinase inhibitor
April 1 - 5, 2017
Washington, D.C., USA